Less use of NSAIDs in long-term than in recent chondroitin sulphate users in osteoarthritis: A pharmacy-based observational study in France

Therapie

Volumn 61, Issue 4, 2006, Pages 341-346

  Lagnaoui, Rajaa ^a,b   Baumevielle, Marie ^a   Bégaud, Bernard ^a   Pouyanne, Pierre ^a   Maurice, Gwenaëlle ^a   Depont, Fanny ^a   Moore, Nicholas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

^b Lagnaoui Consulting   (France)

Author keywords

Analgesics; Chondroitin sulphate; Drug utilization; NSAIDs; Observational study; Osteoarthritis

Indexed keywords

ANALGESIC AGENT; CHONDROITIN SULFATE; CHONDROSULF; CS 400; DIACETYLRHEIN; HYALURONIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OXACEPROL; UNCLASSIFIED DRUG;

ADULT; AGED; CONFERENCE PAPER; DRUG EFFICACY; DRUG USE; DRUG UTILIZATION; FEMALE; FRANCE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OSTEOARTHRITIS; OUTCOME ASSESSMENT; PATIENT CODING; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT DURATION; ARTICLE; CROSS-SECTIONAL STUDY; MIDDLE AGED; PHARMACY;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHONDROITIN SULFATES; CROSS-SECTIONAL STUDIES; DRUG UTILIZATION; FEMALE; FRANCE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PHARMACIES;

EID: 36549028749     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: 10.2515/therapie:2006063     Document Type: Conference Paper

References (27)

1. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum 1998; 41(8): 1343-55
2. Guccione AA, Felson DT, Anderson JJ, et al. The effects of specific medical conditions on the functional limitations of elders in the Framingham Study. Am J Public Health 1994; 84(3): 351-8
3. Reygrobellet C, Le Pen C. COART France 2003 report on new socioeconomic data on osteoarthritis in France. Presse Med 2004; 33 (9 Pt 2): S4-6
4. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312 (7046): 1563-6
5. Garcia Rodriguez LA, Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 2004; 159(1): 23-31
6. Bjordal JM. Ljunggren AE, Klovning A, et al. Non-steroidal antiinflammatory drugs, including cyclo-oxygenase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ 2004; 329 (7478): 1317
7. Hooper L, Brown TJ, Elliott R, et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal antiinflammatory drugs: systematic review. BMJ 2004; 329 (7472): 948
8. Brief AA, Maurer SG, Di Cesare PE. Use of glucosamine and chondroitin sulfate in the management of osteoarthritis. J Am Acad Orthop Surg 2001; 9(2): 71-8
9. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2005; 64(5): 669-81
10. McAlindon TE, La Valley MP, Gulin JP, et al. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. Jama 2000; 283 (11): 1469-75
11. Richy F, Bruyere O, Ethgen O, et al. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003; 163 (13): 1514-22
12. Towheed TE, Anastassiades TP. Glucosamine and chondroitin for treating symptoms of osteoarthritis: evidence is widely touted but incomplete. Jama 2000; 283 (11): 1483-4
13. Clegg DO, Reada DJ, Harris CL, et al. The Efficacy of Glucosamine and Chondroitin Sulfate in Patients with Painful Knee Osteoarthritis (OA): The Glucosamine/chondroitin Arthritis Intervention Trial (GAIT). In: ACR; 2005 Nov 14, 2005; San Diego; 2005
14. Michel BA, Stucki G, Frey D, et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis Rheum 2005; 52 (3): 779-86
15. Imanari T, Toida T, Koshiishi I, et al. High-performance liquid chromatographic analysis of glycosaminoglycan-derived oligosaccharides. J Chromatogr A 1996; 720 (1-2): 275-93
16. Kostoulas G, Horler D, Naggi A, et al. Electrostatic interactions between human leukocyte elastase and sulfated glycosaminoglycans: physiological implications. Biol Chem 1997; 378 (12): 1481-9
17. Pertuiset E. Efficacité thérapeutique des chondroïtines Sulfates dans l'arthrose. Méta-analyse différenciée du Chondrosulf®. Mise au point sur la structure, la sulfatation et le mode d'action. Rev Rhum 2002; 69 Suppl 4: 157-70
18. Morreale P, Manopulo R, Galati M, et al. Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. J Rheumatol 1996; 23 (8): 1385-91
19. Bucsi L, Poor G. Efficacy and tolerability of oral chondroitin sulfate as asymptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 1998; 6 Suppl A: 31-6
20. Leeb BF, Schweitzer H, Montag K, et al. A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. J Rheumatol 2000; 27(1): 205-11
21. Hardingham TE, Venn G, Bayliss MT. Chondrocyte responses in cartilage and in experimental osteoarthritis. Br J Rheumatol 1991; 30 Suppl 1: 32-7
22. Caterson B, Mahmoodian F, Sonell JM, et al. Modulation of native chondroitin sulphate structure in tissue development and in disease. J Cell Sci 1990; 97 (Pt 3): 411-7
23. Jordan KM, Arden NK, Doherty M, et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis 2003; 62(12): 1145-55
24. Henry D, McGettigan P. Epidemiology overview of gastrointestinal and renal toxicity of NSAIDs. Int J Clin Pract Suppl 2003 (135): 43-9
25. Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001; 286 (8): 954-9
26. Juni P, Nartey L, Reichenbach S, et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364 (9450): 2021-9
27. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum 2004; 50(8): 2433-40